In 757 adults with severe hypertriglyceridemia, plozasiran cut acute pancreatitis events by 78% overall and 91% in those with recent prior pancreatitis.
News|Articles|March 28, 2024
Beyond Colonoscopy: Shifting Incidence, Mortality Prompts New Era of Colorectal Cancer Screening
Author(s)Abigail Brooks, MA
The recent rise in colorectal cancer incidence and mortality in younger patients has sparked a serious discussion about strategies to increase screening uptake and adherence, raising questions about the role of noninvasive tests versus the traditional “gold standard,” colonoscopy.
Advertisement
Advertisement
Two decades ago, colorectal cancer was the fourth leading cause of cancer-related death in both men and women under 50 years of age – now, it has jumped to the leading cause in men and the second most common cause in women, behind breast cancer.1
Related to this article
A post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.
Oral icotrokinra beat placebo and was noninferior to ustekinumab in moderate to severe plaque psoriasis in the phase 3 ICONIC-ASCEND trial.
HIBISCUS showed a 48.7% vs 7.2% hemoglobin response at week 24, with an FDA decision expected in 2027.
Experts outline when to stop cycling topical steroids in chronic hand eczema and where topical delgocitinib now fits.
TRANSCEND-T2D-2 topline data show retatrutide lowered A1C more and produced over twice the weight loss of semaglutide 2 mg in type 2 diabetes.
Tom Martens, MD, joins Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss CONNECT trial data on CGM in non-insulin-treated type 2 diabetes.
Leigh Ann Pansch, MSN, FNP-BC, DCNP, discusses year-round photoprotection, missed skin cancer detection, and overlooked patients for Healthy Skin Month.
Advertisement
Advertisement